Prospects for Pharmaceutical Treatment of Achondroplasia
John B. Cannon, Ph.D Achondroplasia is a form of dwarfism that occurs about once in every 20,000 births. It arises from a defect in the process of bone growth in…
News
-
-
Study may change treatment of childhood growth disorders
A child’s growth is often measured by pediatricians during routine physicals to identify abnormalities of growth and stature. An abnormality in these measurements could mean a child has a growth…
-
BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia Data Accepted to ENDO 2020
SAN FRANCISCO, May 11, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in vitro and in vivo data from two studies support QED’s plans to evaluate a…
-
BioMarin – Update for Achondroplasia Associations
As more cases of COVID-19 are confirmed, we recognize the increased challenges and concerns faced by participants in the BioMarin clinical studies. The safety and well-being of study participants, healthcareproviders,…
-
QED COVID-19 Update
Dear Chandler Project, We at QED know that this is a challenging time for all families. We hope that you are all doing well, are safe, and are using this…
-
Study of Infigratinib in Children With Achondroplasia
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in…